BioCurex, Inc.(fka BOCX)

[HALF FULL GLASS]

Gold, Looks to me like the FDA approved another poor Cancer Marker. Biocurex is much better and should fly right through !!!


OBJECTIVE: • To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and = third repeat biopsy session.

PATIENTS AND METHODS: • Patients (n= 127) aged =70 years, with suspicious digital rectal examination (DRE) and/or persistently elevated age-specific total PSA levels (2.5-6.5 ng/mL) and/or suspicious prior histology (atypical small acinar proliferations [ASAPs]= two cores affected by high-grade prostatic intra-epithelial neoplasia [HGPIN]) undergoing either a first, second, or = third repeat biopsy were investigated using a 12- or 24-core biopsy scheme. • PSAV (= three values collected over =12 months) was calculated using the log-slope method. PCA3 scores were assessed using the Progensa assay®. • After stratification according to the number of previous biopsies (first, second and = third), calculation of specificity, positive and negative predictive values (PPV, NPV) and the proportion of avoided unnecessary repeat biopsies (PAB) compared with tPSA at fixed sensitivity thresholds (75, 85 and 95%) were performed. • Finally, accuracy estimates (area under the curve [AUC]) were quantified for each repeat biopsy scenario.

RESULTS: • At repeat biopsy, overall prostate cancer (PCa) detection was 34.6%. • At first repeat biopsy, PCA3 predicted PCa best (AUC = 0.80) and would have avoided 72.2% of repeat biopsies (75% sensitivity) compared with tPSA. • At second repeat biopsy, %fPSA demonstrated the highest accuracy (AUC = 0.82) and would have avoided 66.7% of repeat biopsies (75% sensitivity) compared with tPSA. • At = third repeat biopsy, again %fPSA demonstrated the highest accuracy (AUC = 0.70) and would have avoided 45.0% of repeat biopsies (75% sensitivity) compared with tPSA. • The main limitation of our study resides in its small sample size.CONCLUSIONS: • The findings of the present study promote the concept that the number of previous repeat biopsy sessions strongly influences the performance characteristics of biopsy risk factors. • Total PSA was no significant risk factor in the entire analysis. By contrast, %fPSA performed best at second and = third repeat biopsy. PSAV's diagnostic potential was reserved to patients at second and = third repeat biopsy. • Finally, PCA3 demonstrated the highest diagnostic accuracy and potential to reduce unnecessary biopsies at first repeat biopsy. However, this advantage dissipated at second and = third repeat biopsy.© 2011 THE AUTHORS; BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

http://www.ncbi.nlm.nih.gov/pubmed/21939492